THE RELATIVE VALUE OF CONVENTIONAL STAGING PROCEDURES FOR DEVELOPING PROGNOSTIC MODELS IN EXTENSIVE-STAGE SMALL-CELL LUNG-CANCER

被引:21
作者
SHEEHAN, RG [1 ]
BALABAN, EP [1 ]
COX, JV [1 ]
FRENKEL, EP [1 ]
机构
[1] UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75230 USA
关键词
D O I
10.1200/JCO.1990.8.12.2047
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Published prognostic models for small-cell lung cancer (SCLC) have either combined limited- and extensive-stage patients or have not included standard anatomic staging information to assess the relative value of the knowledge of specific sites and number of sites of metastases in predicting survival in extensive-stage disease. We studied 136 extensive-stage patients in whom traditional staging procedures were performed and in whom other previously demonstrated significant pretreatment variables were determined. Using the Cox proportional hazards model, when all data were included, three variables were significantperformance status (PS) (P= .0001), number of sites of metastases (P = .0010), and age (P = .0029). A prognostic algorithm was developed using these variables, which divided the patients into three distinct groups. When the anatomic staging data were omitted, the serum albumin (P = .0313) was the only variable in addition to PS (P = .0001) and age (P = .0064) that was significant. An alternative algorithm using these three variables was nearly as predictive as the original. Therefore, in extensive-stage patients, reasonable pretreatment prognostic information can be obtained without using the number or specific sites of metastases as variables once the presence of distant metastases has been demonstrated. © 1990 by American Society of Clinical Oncology.
引用
收藏
页码:2047 / 2053
页数:7
相关论文
共 25 条
[1]  
Sheehan R.G., Small cell lung cancer: A problem of tumor heterogeneity, Am J Med Sci, 292, pp. 241-256, (1986)
[2]  
Simon R., Importance of prognostic factors in cancer clinical trials, Cancer Treat Rep, 68, pp. 185-192, (1984)
[3]  
Zelen M., Keynote address on biostatistics and data retrieval, Cancer Chemother Rep, 4, pp. 31-42, (1973)
[4]  
Livingston R.B., Moore T.N., Heilbrun L., Et al., Small-cell carcinoma of the lung: Combined chemotherapy and radiation. A Southwest Oncology Group study, Ann Intern Med, 88, pp. 194-199, (1978)
[5]  
Maurer L.H., Pajak T.F., Prognostic factors in small cell carcinoma of the lung: A Cancer and Leukemia Group B study, Cancer Treat Rep, 65, pp. 767-774, (1981)
[6]  
Roswit B., Patno M.E., Rapp R., Et al., The survival of patients with inoperable lung cancer: A large scale randomized study of radiation therapy versus placebo, Radiology, 90, pp. 688-697, (1968)
[7]  
Ihde D.C., Makuch R.W., Carney D.N., Et al., Prognostic implications of stage of disease and sites of metastases in patients with small cell carcinoma of the lung treated with intensive combination chemotherapy, Am Rev Respir Dis, 123, pp. 500-507, (1981)
[8]  
Souhami R.L., Bradbury I., Geddes D.M., Et al., Prognostic significance of laboratory parameters measured at diagnosis in small cell carcinoma of the lung, Cancer Res, 45, pp. 2878-2882, (1985)
[9]  
Osterlind K., Andersen P.K., Prognostic factors in small cell lung cancer: Multivariate model based on 778 patients treated with chemotherapy with or without radiation, Cancer Res, 46, pp. 4189-4194, (1986)
[10]  
Cerny T., Blair V., Andersen H., Et al., Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients, Int J Cancer, 39, pp. 146-149, (1987)